Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas

Clinical Cancer Research

Volumn 19, Issue 24, 2013, Pages 6830-6841

  Garcia Carracedo, Dario ^a   Turk, Andrew T ^a   Fine, Stuart A ^a   Akhavan, Nathan ^a   Tweel, Benjamin C ^a   Parsons, Ramon ^a   Chabot, John A ^a   Allendorf, John D ^a,c   Genkinger, Jeanine M ^b   Remotti, Helen E ^a   Su, Gloria H ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Columbia University Medical Center ^*  (United States)

^c WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1;

ADULT; AGED; AKT1 GENE; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; MUTATIONAL ANALYSIS; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PTEN GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 84890714103     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0624     Document Type: Article

References (51)

1. Hruban RH, Takaori K, Canto M, Fishman EK, Campbell K, Brune K, et al. Clinical importance of precursor lesions in the pancreas. J Hepatobiliary Pancreat Surg 2007;14:255-63. (Pubitemid 46863914)
2. Kloppel G, Kosmahl M. Cystic lesions and neoplasms of the pancreas. The features are becoming clearer. Pancreatology 2001;1:648-55. (Pubitemid 33674962)
3. Belyaev O, Seelig MH, Muller CA, Tannapfel A, Schmidt WE, Uhl W. Intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol 2008;42:284-94. (Pubitemid 351301495)
4. Andrejevic-Blant S, Kosmahl M, Sipos B, Kloppel G. Pancreatic intraductal papillary-mucinous neoplasms: a new and evolving entity. Virchows Arch 2007;451:863-9. (Pubitemid 350060751)
5. Crippa S, Salvia R, Warshaw AL, Dominguez I, Bassi C, Falconi M, et al. Mucinous cystic neoplasm of the pancreas is not an aggressive entity: lessons from 163 resected patients. Ann Surg 2008;247:571-9. (Pubitemid 351440607)
6. Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788-97; discussion 97-9.
7. Haugk B. Pancreatic intraepithelial neoplasia-can we detect early pancreatic cancer? Histopathology 2010;57:503-14.
8. Furukawa T, Kloppel G, Volkan Adsay N, Albores-Saavedra J, Fukush-ima N, Horii A, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005;447:794-9. (Pubitemid 41728866)
9. Shi C, Hruban RH. Intraductal papillary mucinous neoplasm. Hum Pathol 2012;43:1-16.
10. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
11. Schonleben F, Qiu W, Bruckman KC, Ciau NT, Li X, Lauerman MH, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett 2007; 249:242-8. (Pubitemid 46452934)
12. Schonleben F, Qiu W, Ciau NT, Ho DJ, Li X, Allendorf JD, et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res 2006;12:3851-5. (Pubitemid 44000267)
13. Yamaguchi H, Kuboki Y, Hatori T, Yamamoto M, Shiratori K, Kawa-mura S, et al. Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol 2011;35:1812-7.
14. Z'Graggen K, Rivera JA, Compton CC, Pins M, Werner J, Fernandez-del Castillo C, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg 1997;226:491-8; discussion 8-500.
15. Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994;425:357-67.
16. Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3:92ra66.
17. Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 2011;108:21188-93.
18. Sato N, Rosty C, Jansen M, Fukushima N, Ueki T, Yeo CJ, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucin-ous neoplasms of the pancreas. Am J Pathol 2001;159:2017-22. (Pubitemid 33104257)
19. Su GH, Hruban RH, Bansal RK, Bova GS, Tang DJ, Shekher MC, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999;154:1835-40. (Pubitemid 29262866)
20. Matsubayashi H, Sato N, Fukushima N, Yeo CJ, Walter KM, Brune K, et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res 2003;9:1446-52. (Pubitemid 36418400)
21. Schoedel KE, Finkelstein SD, Ohori NP. K-Ras and microsatellite marker analysis of fine-needle aspirates from intraductal papillary mucinous neoplasms of the pancreas. Diagn Cytopathol 2006;34: 605-8. (Pubitemid 44298560)
22. Wada K, Takada T, Yasuda H, Amano H, Yoshida M, Sugimoto M, et al. Does "clonal progression" relate to the development of intraductal papillary mucinous tumors of the pancreas? J Gastrointest Surg 2004;8:289-96. (Pubitemid 38340607)
23. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004;15:161-70. (Pubitemid 38251644)
24. Bayascas JR. Dissecting the role of the 3-phosphoinositide-depen-dent protein kinase-1 (PDK1) signalling pathways. Cell cycle (Georgetown, Tex 2008;7:2978-82.
25. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev 2002;2:489-501. (Pubitemid 37328931)
26. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63. (Pubitemid 41079915)
27. Hill R, Calvopina JH, Kim C, Wang Y, Dawson DW, Donahue TR, et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res 2010;70:7114-24.
28. Stanger BZ, Stiles B, Lauwers GY, Bardeesy N, Mendoza M, Wang Y, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005;8:185-95. (Pubitemid 41317590)
29. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5.
30. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102. (Pubitemid 29036292)
31. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-8. (Pubitemid 40194293)
32. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle (Georgetown, Tex) 2004;3:1221-4. (Pubitemid 40268595)
33. Garcia-Rostan G, Costa AM, Pereira-Castro I, Salvatore G, Hernandez R, Hermsem MJ, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005;65:10199-207. (Pubitemid 41743711)
34. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutationsin headandnecksquamous cell carcinoma. Clin Cancer Res 2006;12:1441-6.
35. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequencyof mutations of the PIK3CA genein humancancers. Science (New York, NY) 2004;304:554. (Pubitemid 38541907)
36. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006;103:1475-9. (Pubitemid 43191190)
37. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802-7. (Pubitemid 40282746)
38. Samuels Y, Diaz LA Jr., Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73. (Pubitemid 40799249)
39. Lubezky N, Ben-Haim M, Marmor S, Brazowsky E, Rechavi G, Klausner JM, et al. High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN). J Gastrointest Surg 2011;15: 503-11.
40. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44. (Pubitemid 47123510)
41. Bleeker FE, Felicioni L, Buttitta F, Lamba S, Cardone L, Rodolfo M, et al. AKT1(E17K) in human solid tumours. Oncogene 2008;27: 5648-50.
42. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007;12:104-7. (Pubitemid 47199129)
43. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28:977-87. (Pubitemid 38971421)
44. Qiu W, Tong GX, Manolidis S, Close LG, Assaad AM, Su GH. Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer. Int J Cancer 2008;122:1189-94. (Pubitemid 351214020)
45. Zhang R, Zhu Z, Zhu H, Nguyen T, Yao F, Xia K, et al. SNP Cutter: a comprehensive tool for SNP PCR-RFLP assay design. Nucleic Acids Res 2005;33(Web Server issue):W489-92. (Pubitemid 44529968)
46. Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, et al. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 2005;3:493-502. (Pubitemid 41377639)
47. Ikenoue T, Kanai F, Hikiba Y, Tanaka Y, Imamura J, Ohta M, et al. Functional consequences of mutations in a putative Akt phosphor-ylation motif of B-raf in human cancers. Mol Carcinog 2005;43: 59-63. (Pubitemid 40629203)
48. Mohri D, Asaoka Y, Ijichi H, Miyabayashi K, Kudo Y, Seto M, et al. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol 2012;47:203-13.
49. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (New York, NY) 2008;321:1801-6.
50. Mohamedali A, Lea NC, Feakins RM, Raj K, Mufti GJ, Kocher HM. AKT1 (E17K) mutation in pancreatic cancer. Technol Cancer Res Treat 2008;7:407-8.
51. Ban S, Naitoh Y, Mino-Kenudson M, Sakurai T, Kuroda M, Koyama I, et al. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types. Am J Surg Pathol 2006;30:1561-9. (Pubitemid 44808792)